Adora Ndu has served as our Chief Regulatory Affairs Officer since January 2022. Prior to joining BridgeBio, she held various leadership positions at BioMarin Pharmaceutical from 2017 to 2022, including Group Vice President of Worldwide Research and Development Strategy, Scientific Collaborations and Policy, and also Vice President of Regulatory Affairs Policy, Research, Engagement, and International. Dr. Ndu served at the U.S. Food and Drug Administration (FDA) from 2008 to 2016 in several roles of increasing responsibility, including as Director for the FDA’s Division of Medical Policy Development, team leader at the FDA’s Office of Prescription Drug Promotion (OPDP), and post-market safety review with the FDA’s Division of Pharmacovigilance. Dr. Ndu was also a Commander in the United States Public Health Service. Dr. Ndu has served as a member of the board of directors for DBV Technologies (Nasdaq: DBVT) since May 2021. Dr. Ndu received her Doctor of Pharmacy degree from Howard University College of Pharmacy and her JD from the University of Maryland Carey Law School.